AUG 0 6 2004 B

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT

Attorney Docket No.: 016930-005400US

Customer No.: 20350

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

on August 3, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. Mushelf

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GREGORY et al.

Application No.: 10/766,363

Filed: January 27, 2004

For: ADENOVIRAL VECTORS HAVING A PROTEIN IX DELETION

Confirmation No. 2971

Examiner:

Not yet assigned

Art Unit:

Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

<u>AND</u>

PRELIMINARY AMENDMENT

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 15, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing submitted on February 15, 2000 for Application No. 08/328,673, with a filing date of October 25, 1994. In accordance with 37 C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No. 08/328,673 as the computer-readable form for the instant application. A paper copy of the Sequence Listing from Application No.

Appl. No. 10/766,363 Amdt. dated July 1, 2004 Reply to Notice to Comply of June 15, 2004

08/328,673 is submitted herewith. The information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form submitted on February 15, 2000, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 11 of this paper.